These results are in line with the literature, where elevated IL-6 and CRP concentrations are associated with reduced survival in melanoma patients treated with anti-PD-1 monotherapy, or combined with anti-CTLA-4 in dual therapy, or treated with Dacarbazine (chemotherapy) (Laino et al, 2020). Here, CTLA4 is linked to melanoma.